
News|Articles|May 19, 2011
Sarcoma drug ridaforolimus may improve survival
LOS ANGELES (Reuters) - Ariad Pharmaceuticals' experimental cancer drug may improve overall survival in patients with advanced sarcoma, according to data from a phase III trial released Wednesday.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Schizophrenia, Bipolar Disorder, and MDD Linked to Increased Risk for Developing Long COVID
2
MHE Week in Review – White House GLP-1 Deal, AI Spots Cancer Risk and More
3
Health Plans Beware: Keep Contract Language Tight If Your PBM Wants Rebate Guarantees Renegotiated Because of the IRA and Biosimilars | AMCP Nexus 2025
4
PBMs Make a Case for the GLP-1 Teeter Totter: Up on the Pharmacy Benefit, Down on the Medical One | AMCP Nexus 2025
5

















































